Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 20th. Analysts expect Armata Pharmaceuticals to post earnings of ($0.35) per share and revenue of $1.56 million for the quarter.
Armata Pharmaceuticals Trading Up 4.6 %
Shares of ARMP opened at $2.04 on Tuesday. Armata Pharmaceuticals has a 52 week low of $1.80 and a 52 week high of $4.25. The stock has a market capitalization of $73.81 million, a PE ratio of -1.24 and a beta of 0.87.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Stories
- Five stocks we like better than Armata Pharmaceuticals
- The Basics of Support and Resistance
- Can TikTok Stock Picks Really Make You Rich?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- The “Quality” Rotation: Back to Basics Investing
- Differences Between Momentum Investing and Long Term Investing
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
